SCHEMBL5083062

SCHEMBL5083062

Cc1cccc(Nc2ncccc2C(N)=O)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.72
MAPT P10636 5/20 0.72
NPC1 O15118 4/20 0.72
SMN1; SMN2 Q16637 4/20 0.72
AHR P35869 1/20 0.72
LMNA P02545 2/20 0.71
ALDH1A1 P00352 4/20 0.65
MEN1 O00255 3/20 0.65
KMT2A Q03164 3/20 0.65
KCNH2 Q12809 3/20 0.65
HPGD P15428 2/20 0.56
SYK P43405 9/20 0.55
AURKB Q96GD4 2/20 0.55
ZAP70 P43403 1/20 0.55
HTT P42858 2/20 0.54
PKM P14618 1/20 0.54
MAPK1 P28482 1/20 0.54
DHODH Q02127 1/20 0.52
KDM4E B2RXH2 1/20 0.51
HSD17B10 Q99714 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10144303 0.87 MEN1 (0.71) RAB9AMAPTNPC1SMN1; SMN2AHR
SCHEMBL7272758 0.85 KMT2A (0.60) RAB9AMAPTNPC1SMN1; SMN2AHR
SCHEMBL28282946 0.84 LMNA (0.73) RAB9AMAPTNPC1SMN1; SMN2AHR
SCHEMBL28824955 0.84 RAB9A (1.00) RAB9AMAPTNPC1SMN1; SMN2AHR
SCHEMBL29898269 0.84 RAB9A (1.00) RAB9AMAPTNPC1SMN1; SMN2AHR
SCHEMBL28949487 0.83 LMNA (0.71) RAB9AMAPTNPC1SMN1; SMN2AHR
SCHEMBL28824958 0.83 RAB9A (0.78) RAB9AMAPTNPC1SMN1; SMN2AHR
SCHEMBL5255345 0.83 LMNA (0.71) RAB9AMAPTNPC1SMN1; SMN2AHR
SCHEMBL9496511 0.83 LMNA (1.00) RAB9AMAPTNPC1SMN1; SMN2AHR
SCHEMBL29898238 0.83 LMNA (0.71) RAB9AMAPTNPC1SMN1; SMN2AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103282352-A Benzamides and nicotinamides as syk modulators PORTOLA PHARM INC 2013-09-04 CN claimed
CN-103282352-A Benzamides and nicotinamides as syk modulators PORTOLA PHARM INC 2013-09-04 CN disclosed
US-20080132505-A1 Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine GLAXO GROUP LIMITED 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132505-A1 Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine CNR2, CNR1, PDE4A RAB9A 2120/4885MAPT 3180/4885NPC1 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.